Literature DB >> 6907020

The use of clonidine in detoxification from opiates.

H D Kleber, M S Gold, C E Riordan.   

Abstract

Use of clonidine hydrochloride in detoxification from opiates has demonstrated that this substance can rapidly suppress the signs and symptoms associated with opiate withdrawal. Clonidine hydrochloride, an alpha-adrenergic agonist, is a non-opiate substance. Studies to date indicate that clonidine is useful for withdrawal from methadone maintenance, where it can help in detoxifying the patient in less than 14 days (instead of the usual three to six months) with a high rate of success in achieving zero dosage. The results of a clinical investigation of clonidine are presented and discussed in this paper. It has been shown to suppress signs and symptoms of opiate withdrawal in patients taking up to 75 mg of methadone daily. Shorter-acting narcotics may be withdrawn in less than a week. To prevent relapse, post-detoxification counselling and the use of the narcotic antagonist, naltrexone, are recommended.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6907020

Source DB:  PubMed          Journal:  Bull Narc        ISSN: 0007-523X


  10 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

2.  Substance Use Disorder Counselors' Reports of Tobacco Cessation Services Availability, Implementation, and Tobacco-related Knowledge.

Authors:  Jessica L Muilenburg; Tanja C Laschober; Lillian T Eby
Journal:  J Adolesc Health       Date:  2015-09       Impact factor: 5.012

3.  Clonidine therapy for narcotic withdrawal.

Authors:  P Devenyi; A Mitwalli; W Graham
Journal:  Can Med Assoc J       Date:  1982-11-15       Impact factor: 8.262

4.  Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.

Authors:  Zoe M Weinstein; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong Kim; Gabriela Gryczynski; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2016-11-05       Impact factor: 4.492

5.  Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys.

Authors:  L R Gerak; C Zanettini; W Koek; C P France
Journal:  Psychopharmacology (Berl)       Date:  2015-07-23       Impact factor: 4.530

6.  Precipitated and conditioned withdrawal in morphine-treated rats.

Authors:  Ginger L Becker; Lisa R Gerak; Jun-Xu Li; Wouter Koek; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2010-02-03       Impact factor: 4.530

7.  Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.

Authors:  L R Gerak; C P France
Journal:  J Pharmacol Exp Ther       Date:  2016-03-02       Impact factor: 4.030

8.  Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys.

Authors:  G L Becker; L R Gerak; W Koek; C P France
Journal:  Psychopharmacology (Berl)       Date:  2008-08-23       Impact factor: 4.530

9.  Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.

Authors:  Matisyahu Shulman; Tse-Hwei Choo; Jennifer Scodes; Martina Pavlicova; Jonathan Wai; Patrick Haenlein; Babak Tofighi; Aimee N C Campbell; Joshua D Lee; John Rotrosen; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2021-01-16

Review 10.  Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?

Authors:  Mark S Gold; David Baron; Abdalla Bowirrat; Kenneth Blum
Journal:  J Neurol Sci       Date:  2020-09-15       Impact factor: 3.181

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.